EMERGENT BIOSOLUTIONS REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS
Emergent BioSolutions Inc. (EBS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EMERGENT BIOSOLUTIONS REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS • Third Quarter 2026 Total Revenues of $110.0 million • Third Quarter 2026 Net Loss of $32.7 million and Net Loss Margin was (30)% • Third Quarter 2026 Adjusted Net Loss of $18.7 million • Third Quarter 2026 Gross
How this was made
The 30-second read
Why it matters
The earnings miss and guidance shortfall suggest continued cash‑burn and may trigger short‑term price weakness.
Market read
EBS's earnings release provides fresh, material information that could influence short‑term trading decisions in the biotech sector.
What to watch
The $75M note repurchase and new CFO transition could improve balance‑sheet flexibility, which some investors might view positively.
Third Quarter 2026 Total Revenues of $110.0 million; Net Loss of $32.7 million; Adjusted EBITDA loss of $4.6 million; full-year 2026 total-revenue forecast revised to $600 - $645 million.
Q3 total revenues declined 52% to $110.0 million, gross margin fell to 14%, and the company recorded a $32.7 million net loss and $4.6 million Adjusted EBITDA loss. Full-year revenue, adjusted net income, and Adjusted EBITDA guidance were revised downward.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Q3 2026 Total revenuesGAAP | $110M | – | (52) % |
| Q3 2026 Product and services sales, netGAAP | $106.4M | – | – |
| Q3 2026 Contracts and grantsGAAP | $3.6M | – | – |
| Q3 2026 Cost of product and services sales, netGAAP | $80.8M | – | (6) % |
| Q3 2026 Gross marginGAAP | $15M | – | – |
| Q3 2026 Gross margin %GAAP | 14 % | – | – |
| Q3 2026 Adjusted gross marginnon-GAAP | $29.7M | – | – |
| Q3 2026 Adjusted gross margin %non-GAAP | 28 % | – | – |
| Q3 2026 Research and developmentGAAP | $9.4M | – | (30) % |
| Q3 2026 Selling, general and administrativeGAAP | $46.5M | – | 20 % |
| Q3 2026 Amortization of intangible assetsGAAP | $10.6M | – | (35) % |
| Q3 2026 Total operating expensesGAAP | $147.3M | – | (5) % |
| Q3 2026 Income (loss) from operationsGAAP | −$37.3M | – | – |
| Q3 2026 Interest expenseGAAP | −$9.7M | – | – |
| Q3 2026 Net income (loss)GAAP | −$32.7M | – | (164) % |
| Q3 2026 Net income (loss) per diluted shareGAAP | $(0.64) | – | (170) % |
| Q3 2026 Net income (loss) marginGAAP | (30) % | – | – |
| Q3 2026 Adjusted net income (loss)non-GAAP | −$18.7M | – | (129) % |
| Q3 2026 Adjusted net income (loss) per diluted sharenon-GAAP | $(0.36) | – | (131) % |
| Q3 2026 Adjusted EBITDAnon-GAAP | −$4.6M | – | (105) % |
| Q3 2026 Adjusted EBITDA marginnon-GAAP | (4) % | – | – |
| Q3 2026 Capital expendituresother | $3.3M | – | (3) % |
| Q3 2026 Capital expenditures as a % of total revenuesother | 3 % | – | – |
| Nine months ended September 30, 2026 Total revenuesGAAP | $500.4M | – | (16) % |
| Nine months ended September 30, 2026 Gross marginGAAP | $188.7M | – | – |
| Nine months ended September 30, 2026 Gross margin %GAAP | 39 % | – | – |
| Nine months ended September 30, 2026 Impairment of long-lived assetsGAAP | $191.3M | – | – |
| Nine months ended September 30, 2026 Income (loss) from operationsGAAP | −$151.9M | – | – |
| Nine months ended September 30, 2026 Net income (loss)GAAP | −$206.1M | – | (292) % |
| Nine months ended September 30, 2026 Net income (loss) per diluted shareGAAP | $(3.99) | – | (311) % |
| Nine months ended September 30, 2026 Adjusted net incomenon-GAAP | $24.1M | – | (80) % |
| Nine months ended September 30, 2026 Adjusted net income per diluted sharenon-GAAP | $0.47 | – | (78) % |
| Nine months ended September 30, 2026 Adjusted EBITDAnon-GAAP | $127.5M | – | (38) % |
| Nine months ended September 30, 2026 Adjusted EBITDA marginnon-GAAP | 25 % | – | – |
| Nine months ended September 30, 2026 Adjusted gross marginnon-GAAP | $238.9M | – | – |
| Nine months ended September 30, 2026 Adjusted gross margin %non-GAAP | 49 % | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| Commercial ProductsRevenue declined $31.4 million, primarily due to lower sales of OTC NARCAN® driven mostly by an unfavorable price-volume mix in U.S. public interest channels, partially mitigated by increased Canadian sales of branded NARCAN®. | $43.5M | – | (42) % |
| MCM ProductsRevenue declined $83.1 million. The quarter included higher USG CYFENDUS® sales due to timing, offset by lower USG ACAM2000® and BAT® sales due to timing and lower CNJ-016® international sales. | $59.4M | – | (58) % |
| NaloxoneLower OTC NARCAN® sales, mostly from an unfavorable price-volume mix in U.S. public interest channels, partially mitigated by increased Canadian branded NARCAN® sales. | $43.5M | – | (42) % |
| Anthrax MCMHigher USG sales of CYFENDUS® due to timing. | $25.1M | – | NM |
| Smallpox MCMLower USG ACAM2000® sales due to timing, lower USG and international CNJ-016® sales, partially offset by higher TEMBEXA® USG sales due to timing. | $26.7M | – | (68) % |
| Other ProductsLower USG BAT® sales due to timing, partially offset by increased international BAT sales. | $7.6M | – | (87) % |
| All other revenuesServices revenue declined due to less production activity at the Winnipeg facility, while contracts and grants revenue declined due to lower Ebanga® related development work. | $7.1M | – | (48) % |
2026 Full Year Forecast outlook
- Revenue$600 - $645
- Gross margin45% - 47% Adjusted gross margin %
- NoteNet loss: $(255) - $(225)
- NoteAdjusted net income (loss): ($10) - $20
- NoteAdjusted EBITDA: $110 - $140
- NoteProduct and services sales, net: $578 - $620
- NoteGross margin: $195 - $226
- NoteGross margin %: 34% - 36%
- NoteAdjusted gross margin: $260 - $291
- NoteInterest expense: ~$38
- NoteR&D: ~6% of Revenue
- NoteSG&A: ~28-30% of Revenue
- NoteWeighted average fully diluted share count: ~52
- NoteStock-based compensation expense: ~$19
- NoteCapex: ~$16
- NoteDepreciation & amortization: ~$81
Capital returns
- Completed repurchase of $75 million aggregate principal amount of Senior Unsecured Notes.
- Nine months ended September 30, 2026 repurchase of debt: $(68.1) million.
- Nine months ended September 30, 2026 purchases of treasury stock: $(18.1) million.
- Treasury stock at September 30, 2026: $(270.7) million.
What drove it
- Anthrax MCM revenue increased $23.7 million due primarily to higher USG CYFENDUS® sales due to timing.
- The company was awarded a contract modification valued at approximately $24 million for CYFENDUS®.
- The company completed restructuring efforts intended to improve cost structure, drive efficiencies and align resourcing to current organizational needs.
- R&D expense decreased $4.1 million, primarily from reduced Ebanga® development work and other unfunded R&D project spend.
- Q3 interest expense declined to $(9.7) million from $(15.2) million.
Concerns
- Total revenues declined $121.1 million, or 52%, from Q3 2025.
- Naloxone revenue declined $31.4 million, or 42%, amid an unfavorable OTC NARCAN® price-volume mix in U.S. public interest channels.
- Smallpox MCM revenue declined $56.9 million, or 68%, primarily due to timing of USG ACAM2000® and CNJ-016® sales.
- Other Products revenue declined $49.9 million, or 87%, primarily due to lower USG BAT® sales due to timing.
- Q3 gross margin % was 14%, compared with 54% in Q3 2025; MCM Products gross margin % was 19%, compared with 68%.
- SG&A increased $7.6 million, or 20%, due in part to a prior-year litigation insurance reimbursement and current-year severance costs.
- The nine-month period included $191.3 million of impairment of long-lived assets.
- Full-year 2026 total revenue, adjusted net income (loss), and Adjusted EBITDA outlooks were revised downward.
What to watch
- Timing of annual USG purchase options, USG purchases, governmental funding and deliveries under MCM procurement contracts.
- Commercial performance and price-volume mix for OTC NARCAN® in U.S. public interest channels.
- CYFENDUS® contract execution and the approximately $24 million contract modification.
- Delivery of restructuring benefits and the effect of severance and restructuring costs.
- Debt reduction, compliance with operating and financial covenants, and operating cash flow.
- Transition of the CFO role, with Rich Lindahl retiring effective December 31, 2026 and Frank Vargo becoming interim Chief Financial Officer beginning January 1, 2027.
Balance sheet and cash flow
- Cash and cash equivalents at September 30, 2026: $175.7 million; December 31, 2025: $205.4 million.
- Restricted cash at September 30, 2026: $1.2 million; December 31, 2025: $3.7 million.
- Debt at September 30, 2026: $507.7 million; December 31, 2025: $572.1 million.
- Total assets at September 30, 2026: $995.2 million; December 31, 2025: $1,318.6 million.
- Total liabilities at September 30, 2026: $682.0 million; December 31, 2025: $796.0 million.
- Total stockholders’ equity at September 30, 2026: $313.2 million; December 31, 2025: $522.6 million.
- Nine months ended September 30, 2026 net cash provided by operating activities: $122.4 million; nine months ended September 30, 2025: $92.9 million.
- Nine months ended September 30, 2026 purchases of property, plant and equipment: $(7.8) million; nine months ended September 30, 2025: $(9.9) million.
- Nine months ended September 30, 2026 net cash used in investing activities: $(50.1) million; nine months ended September 30, 2025 net cash provided by investing activities: $73.3 million.
- Nine months ended September 30, 2026 net cash used in financing activities: $(104.5) million; nine months ended September 30, 2025: $(22.7) million.
- Cash, cash equivalents and restricted cash at September 30, 2026: $176.9 million; September 30, 2025: $249.2 million.
Analysis
Emergent reported a sharply weaker third quarter. Total revenues were $110.0 million, down 52% from $231.1 million in Q3 2025, producing a GAAP net loss of $32.7 million and an Adjusted EBITDA loss of $4.6 million. The revenue result was described as inline with company guidance, but the quarter showed broad declines across Naloxone, Smallpox MCM and Other Products. Anthrax MCM was the exception, increasing $23.7 million on higher USG CYFENDUS® sales due to timing.
Product mix and volume pressured profitability. GAAP gross margin was $15.0 million and gross margin % was 14%, compared with $119.8 million and 54% in the prior-year quarter. Adjusted gross margin % fell to 28% from 62%. Commercial Products gross margin % declined to 26% amid an unfavorable OTC NARCAN® price and volume mix across most U.S. channels. MCM Products gross margin % declined to 19%, with the company citing an unfavorable sales mix and lower volumes that reduced absorption of fixed manufacturing costs.
Operating expenses declined only 5% to $147.3 million as lower cost of product and services sales, R&D and intangible amortization were partially offset by a 20% increase in SG&A. The SG&A increase reflected a one-time litigation insurance reimbursement in the prior-year period and severance costs associated with the August 2026 restructuring plan. For the first nine months, GAAP net loss was $(206.1) million, including $191.3 million of impairment of long-lived assets, while adjusted EBITDA was $127.5 million versus $204.8 million in the prior-year period.
Cash generation improved over the nine-month period, with net cash provided by operating activities of $122.4 million versus $92.9 million a year earlier. Cash and cash equivalents were $175.7 million at September 30, 2026, and debt was $507.7 million, compared with $205.4 million and $572.1 million, respectively, at December 31, 2025. The company also completed repurchase of $75 million aggregate principal amount of Senior Unsecured Notes.
The updated full-year forecast lowers total revenues to $600 - $645 from $645 - $675, Adjusted EBITDA to $110 - $140 from $130 - $150, and adjusted net income (loss) to ($10) - $20 from $10 - $30. The net-loss range was revised to $(255) - $(225) from $(245) - $(225). The company raised adjusted gross margin % guidance to 45% - 47% from 42% - 44%, while forecasting full-year gross margin % of 34% - 36%.
Management, verbatim
Emergent's third-quarter results, which include revenue of $110.0 million inline with our guidance, were primarily driven by our diverse biodefense/medical countermeasures and naloxone portfolio, underscoring the importance of disciplined execution as we advance our multi-year transformation.
Joe Papa, president and chief executive officer
We remain focused on our turnaround priorities and strengthening our financial position, which includes improving operating performance, reducing debt, creating long-term shareholder value, continuously demonstrating high standards of quality and compliance in all we do and delivering on our mission to protect and save lives.
Joe Papa, president and chief executive officer
Not in the filing
stated, not guessed- Prior-quarter comparisons for Q3 2026 key metrics were not provided.
- Quarterly operating cash flow was not provided.
- Free cash flow was not provided.
- Dividend information was not provided.
- A prior-release outlook was not provided for comparison with actual results; the filing includes prior full-year guidance ranges but does not provide full-year 2026 actual results.
- Operating-expense guidance was not provided as a total dollar amount.
- Tax-rate guidance was not provided.
AlphAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
Emergent BioSolutions is a biodefense and medical countermeasure company that relies heavily on U.S. government contracts for its anthrax and opioid products.
Ticker impact
Emergent BioSolutions reported Q3 2026 results with revenue down 52% YoY and a net loss of $32.7M.
likely pressure as the market prices in weaker earnings and margin compression
The earnings release shows a 52% revenue drop and a net loss margin of 30%, which typically triggers sell‑side sentiment for a biotech with limited cash flow.
Market effects
Biodefense and opioid‑overdose product segments face demand volatility, potentially pressuring peers.
U.S. biotech sector may see modest downside as investors reassess exposure to government‑contract reliant firms.
Limited; the news is company‑specific with minor spillover to the broader healthcare market.
Counterpoint
If the company can successfully execute its restructuring and secure additional government contracts, the stock may be undervalued after the sell‑off.
Key entities
- ExecutiveJoe Papa
President and CEO of Emergent BioSolutions, quoted in the filing.
- ExecutiveRich Lindahl
Outgoing CFO, retiring Dec 31, 2026.
